A recent drug industry-funded white paper drew a connection between 340B and increases in commercial insurance premiums, but provider advocates and attorneys criticized its methodology and findings.
Drug Industry-Funded White Paper Ties 340B to Rising Commercial Insurance Premiums; Provider Advocates Criticize Study
The 340B program is driving up employer-sponsored health insurance premiums, according to a drug industry-funded white paper. Provider advocates criticized [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
